博来霉素电化学治疗基底细胞癌的系统综述
本系统综述检索MEDLINE、Embase、Web of Science和Cochrane数据库,纳入32项博来霉素电化学治疗基底细胞癌(BCC)研究,仅1项为随机对照试验(RCT)。该RCT显示65个经治BCC在2个月后完全缓解率92%,再治疗后达100%,复发风险低;因缺乏RCT且研究异质性大,未行Meta分析。
要点
- 博来霉素电化学治疗BCC的RCT显示2个月完全缓解率92%,再治疗后100%。
- 仅1项RCT纳入,证据等级有限,未进行Meta分析。
- 未来需大型RCT比较博来霉素电化学治疗与标准治疗。
核心结论
- 基于RCT结果和总体数据,博来霉素电化学治疗BCC显示高完全缓解率和低复发风险。
- 未来研究应包含大型RCT比较博来霉素电化学治疗与标准治疗、成本分析和临床可行性。
研究设计与样本
- 系统综述,检索MEDLINE、Embase、Web of Science和Cochrane数据库。
- 纳入32项博来霉素电化学治疗BCC研究:1项RCT、15项非对照临床试验、3项注册研究、6项前瞻性病例系列和7项回顾性病例系列。
- RCT的Cochrane偏倚风险评估发现一些次要问题,但无预测偏倚风险。
- 研究按博来霉素给药途径分组:静脉(n=14)、病灶内(n=9)和混合报告/使用(n=9)。
- 因缺乏RCT和研究异质性,未进行Meta分析。
主要发现
- RCT结果显示65个经博来霉素电化学治疗的BCC在2个月后完全缓解率92%,再治疗后改善至100%,复发风险低。
- RCT结果总体反映其他纳入研究的发现。
局限性
- 仅1项RCT,缺乏随机对照证据。
- 纳入研究异质性大,无法进行Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Basal cell carcinoma (BCC) is the most common type of cancer and an increasing incidence stimulates the interest in new treatments such as electrochemotherapy (ECT) with bleomycin. This systematic review focuses on literature from the MEDLINE, Embase, Web of Science, and Cochrane databases. Bleomycin-ECT studies (n = 32) were sorted by the level of evidence adjusted for their BCC data only. The studies included a single randomised controlled trial (RCT), 15 uncontrolled clinical trials, three registry studies, six prospective case series and seven retrospective case series. A Cochrane risk-of-bias assessment of the RCT identified some minor concerns but no predicted risk of bias. The studies were also grouped by bleomycin administration routes: intravenous (n = 14), intralesional (n = 9) and mixed reporting/usage (n = 9). A meta-analysis was not conducted due to the lack of RCTs and the heterogeneity of the included studies. The results of the RCT generally reflected the findings of the other included studies and showed a 92% complete response in 65 bleomycin-ECT-treated BCCs after 2 months, improving to 100% after re-treatment, with a low risk of recurrence. Based on the RCT results and overall data, future studies on BCC treatment with bleomycin-ECT should include large RCTs that compare bleomycin-ECT with standard of care, cost analyses, and clinical feasibility.
引用
- Hendel K, Jemec GBE, Haedersdal M, et al. Electrochemotherapy with bleomycin for basal cell carcinomas: a systematic review. J Eur Acad Dermatol Venereol. 2021. PMID: 34219303. doi:10.1111/jdv.17492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。